Wolfe Research initiated coverage of Tango Therapeutics (TNGX) with a Peer Perform rating and no price target Vopimetostat’s signal in pancreatic cancer “looks weak,” the analyst tells investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX:
- Tango Therapeutics Reports Promising Q3 2025 Results
- Tango Therapeutics reports Q3 EPS 14c, consensus (7c)
- Tango Therapeutics, Inc. (TNGX) Q3 Earnings Cheat Sheet
- Tango Therapeutics Advances Innovative Cancer Treatment with S095035 Clinical Trial
- Revolution Medicines and Tango Therapeutics Advance in Targeted Cancer Therapy Study